While highly active during development, Wnt/β-catenin signaling becomes quiescent in adult kidneys and reactivates during kidney injury (7-10). Activation of this signaling leads to a fibrotic response and promotes the progression of CKD via the upregulation of profibrotic mediators, such as fibronectin, the renin-angiotensin system, plasminogen activator inhibitor-1, and [11][12][13]. Induction of MMP-7 by Wnt/β-catenin is particularly interesting, because it is the most robust β-catenin downstream target, and its expression primarily occurs in renal tubules (14-16). As a secreted protein that can be detected in the urine, MMP-7 is an effective noninvasive urinary biomarker for activation of Wnt/β-catenin after kidney injury (16,17).In the current study, we evaluated kidney injury after chronic infusion of angiotensin II (Ang II) using conditional knockout mice with tubule-specific ablation of β-catenin (18). Interestingly, although the genetic mutation was restricted to renal tubules, we found that these mice had significant protection against glomerular injury and proteinuria, accompanied by a reduced MMP-7 expression. These results were replicated in an Adriamycin-induced proteinuria model. We further demonstrate that MMP-7 could degrade the slit diaphragm protein nephrin and impaired integrity of the glomerular filtration barrier. In vivo exposure of mice to elevated MMP-7 levels was sufficient to cause proteinuria, and global ablation of MMP-7 protected mice from Ang II-induced glomerular injury. Our findings illustrate that tubular injury promotes glomerular damage by β-catenin-driven release of MMP-7.